On point in primary CNS lymphoma.

Area of Science:

• Neuro-oncology
• Hematology
• Precision Medicine

Background:

• Primary CNS lymphoma (PCNSL) is an aggressive brain tumor with complex pathogenesis.
• Current treatment strategies face challenges in efficacy and minimizing toxicity.
• Understanding the tumor microenvironment and resistance mechanisms is crucial.

Purpose of the Study:

• To review current challenges and emerging strategies in PCNSL diagnosis and treatment.
• To highlight the role of molecular diagnostics, imaging, and novel therapeutic agents.
• To discuss the impact of the blood-brain barrier on treatment efficacy.

Main Methods:

• Review of current literature on PCNSL diagnosis, treatment, and emerging technologies.
• Analysis of early-phase clinical investigations of targeted agents.
• Discussion of molecular pathways and tumor microenvironment factors.

Main Results:

• The B-cell receptor (BCR) pathway, involving MYD88 and CD79B, is critical in PCNSL pathogenesis.
• Ibrutinib and IMiD agents show promise, but resistance mechanisms require further study.
• The blood-brain barrier remains a significant challenge for drug delivery.

Conclusions:

• Molecular diagnostics and imaging are essential for refining treatment delivery and response assessment.
• Targeting the BCR pathway and overcoming tumor immunosuppression are key therapeutic goals.
• Innovative drug delivery strategies are needed to improve outcomes for PCNSL patients.